Spectrum Pharmaceuticals, Inc.

University of Illinois

Supergen, Inc

Luigi Lenaz

Guru Reddy

Anil Gulati

Bastiaan Nuijen

Dorla Mirejovsky

Ernie Pfadenhauer

Jos H Beijnen

Anthony W Tolcher

Shanta Chawla

Hak Choy

Mario Beer

Reddy Guru

Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ET) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.

Treatment of primary and metastatic carcinoma

Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Bladder cancer treatment and methods

Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETagonist IRL1620.

Sensitization of tumor cells to radiation therapy through administration of endothelin agonists

Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.

Methods, compositions and articles of manufacture for contributing to the treatment of cancers

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).

Methods and compositions for contributing to the treatment of cancers

Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Disclosed is a method of enhancing the therapeutic effect of radiation in a host being treated for cancer including coadministering the radiation and an orally dosed camptothecin derivative to the host being treated for cancer. Also disclosed is a method of enhancing the therapeutic effect of radiation in a host being treated for cancer including orally dosing the host being treated for cancer with a camptothecin derivative; and administering radiation at a point when a serum concentration of the camptothecin derivative in the host being treated for cancer reaches about 50% or more of the maximum concentration achieved by the oral dose.

Growing community of inventors

Newtown, PA, United States of America

Luigi Lenaz